Discounted Cash Flow
Can-fite Biopharma Ltd. ADR
—
—
⚠ Cash flow predictability 63/100 (moderate) —
FCF YoY std dev 47%,
net income 38% (full history)
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $192.3k | $9.6m | $-40.1m | 5004.2% | $0.96 |
| 2017 | $919.3k (378.2%) | $7.4m (-23.2%) | $-11.1m (72.2%) | 803.4% (-83.9%) | $0.15 (-84.4%) |
| 2018 | $4.5m (384.2%) | $7.7m (3.7%) | $-4.9m (56.2%) | 172.0% (-78.6%) | $0.17 (13.3%) |
| 2019 | $2.4m (-46.8%) | $-11.2m (-245.9%) | $-12.6m (-158.0%) | -471.8% (-374.3%) | $-0.11 (-164.7%) |
| 2020 | $889.0k (-62.5%) | $-16.8m (-50.7%) | $-14.1m (-11.9%) | -1892.9% (-301.2%) | $-0.04 (63.6%) |
| 2021 | $993.9k (11.8%) | $-14.7m (12.7%) | $-11.5m (18.4%) | -1478.9% (21.9%) | $-0.03 (25.0%) |
| 2022 | $943.8k (-5.0%) | $-11.9m (19.4%) | $-12.6m (-9.5%) | -1255.9% (15.1%) | $-0.01 (66.7%) |
| 2023 | $865.7k (-8.3%) | $-8.9m (25.0%) | $-9.8m (21.9%) | -1027.5% (18.2%) | $-0.01 (0.0%) |
| 2024 | $785.3k (-9.3%) | $-9.2m (-3.2%) | $-8.9m (9.5%) | -1169.1% (-13.8%) | $0.00 (100.0%) |
| 2025 | $471.9k (-39.9%) | $-11.5m (-24.7%) | $-10.4m (-17.1%) | -2426.7% (-107.6%) | $-5.97 |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
SEC filings report in EUR. Values above are converted to USD for comparison with the US-listed share price.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Net debt deduction: —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.